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1. Introduction 
1.1 Anatomy of the human cardiac conduction system  
1.1.1 Sinoatrial node 
Sinoatrial node (SAN) serves as the natural pacemaker of the heart. It is a spindle shaped 
structure that is located at the junction of the superior vena cava and right atrium.  
The electrical excitation during sinus heart rhythm originates from the SAN and spreads 
to the other regions of the heart. It receives arterial supply from either the right coronary 
artery (60 % of the time) or the left circumflex coronary artery (40-45% of the time). It is 
innervated with postganglionic adrenergic and cholinergic nerve terminals. The discharge 
rate of SAN is modulated by stimulation of beta adrenergic and muscarinic (cholinergic) 
receptors. Stimulation of beta-1 and beta-2 receptors results in positive chronotropic 
response where as stimulation of muscarinic M2 receptors results in negative 
chronotropic response. 
1.1.2 Atrioventricular node 
Atrioventricular node (AVN) is located right above the insertion of the septal leaflet of the 
tricuspid valve beneath the right atrial endocardium. It receives arterial supply from the AV 
nodal branch of the right coronary artery (85%-90% of the time) or left circumflex coronary 
artery (15 % of the time). Action potential from the SAN travels through the atrial 
myocardium to the AVN. The AVN serves to delay the atrial impulse transmission to the 
ventricles and thus coordinates atrial and ventricular contractions.  
1.2 Bundle of His and bundle branches 
Bundle of His is the continuation of the penetrating portion of the atrioventricular bundle on 
the ventricular side. It divides into the right and left bundle branches. It is supplied by the 
left anterior descending and posterior descending arteries. Thus it is relatively protected 
from ischemic damage. 
The bundle branches begin at the superior margin of the muscular interventricular septum 
and divide into the left bundle branch, which may further divide into the anterosuperior 
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branch and central branch and the right bundle branch, which traverses along the right side 
of the interventricular septum. 
1.3 Purkinje fibers 
These fibers form an interweaving network on the endocardial surface of the myocardium 
and are connected to the ends of the bundle branches. They conduct the cardiac impulse 
simultaneously to both the ventricles. 
1.4 Normal sinus rhythm 
Normal sinus rhythm refers to generation of impulse from the SAN at a rate of 60-100 
beats/min in an adult (Fig 1). In adults, rates below 60 beats/min are referred to as 
bradycardia and rates above 100 beats/min are referred to as tachycardia. The normal 
sequence of electrical activation originates from the SAN and spreads through the atria to 
the AVN and His Purkinje system and finally to the ventricular myocardium. 
 
Fig. 1. Normal sinus rhythm 
2.Tachycardia  
Tachycardias are characterized on the basis of origin; those that originate above the ventricle 
are referred to as supraventricular tachycardias (SVTs) and those that originate from the 
ventricle or purkinje fibers are characterized as ventricular tachycardias. The distinction 
between the two types of tachycardias is critical at the beginning due to difference in their 
prognosis. Ventricular tachycardias overall have grave prognosis and usually result from 
significant heart disease. On the other hand, SVTs are usually nonlethal and have a more 
benign prognosis. 
2.1 Narrow and wide complex tachycardia 
Based on the duration of QRS complex on electrocardiogram (ECG), tachycardias can be 
divided into narrow and wide QRS complex tachycardias. Narrow QRS complex 
tachycardias have a QRS complex duration of less than 120 ms and wide QRS complex 
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tachycardias have a QRS complex duration of more than 120 ms. Wide complex 
tachycardias are due to ventricular origin of the tachycardia. Ventricular origin of the 
tachycardia results in slow conduction of electrical impulses across the ventricular 
myocardium due to longer conduction velocity of the ventricular myocardium unlike 
narrow complex tachycardia which are conducted over the normal conduction system 
which has faster conduction velocity resulting in narrow QRS complex on the surface 
electrocardiogram. Wide complex tachycardia however can be supraventricular in origin if 
there is pre-existing bundle branch block in either of bundles or if there is activation of the 
ventricles over the accessory bypass tract and subsequent spread of electrical activation 
through the ventricular myocardium resulting in a wider QRS complex. 
2.2 Sinus tachycardia 
Sinus tachycardia as the name suggests originates from the SAN and has a rate of more than 
100 beats/min (Fig 2). 
 
Fig. 2. Sinus tachycardia 
It has a gradual onset and termination. It is characterized by presence of sinus P waves prior 
to each QRS complex on ECG. It is usually caused by increase in adrenergic discharge or 
decrease in parasympathetic discharge.  
It is common during infancy and childhood. The maximum heart rate achieved is higher in 
young individuals and decreases with age. In adults, it occurs in response to various 
physiologic or pathological stresses such as exercise, fever, anxiety, thyrotoxicosis, anemia 
and shock. It may result from consumption of drugs such as atropine, amphetamines, 
caffeine and alcohol. Sinus tachycardia is often benign by itself and is usually a 
manifestation of underlying causes as mentioned above. Thus treatment of sinus 
tachycardia requires treatment of the underlying cause. 
2.3 Inappropriate Sinus Tachycardia (IST) 
Is a syndrome that can occur due to increased automaticity of the SAN or an automatic atrial 
focus present near the SAN. It may occur due to an imbalance in the vagal and sympathetic 
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control of the SAN. Treatment of IST involves treatment with beta-blockers or calcium 
channel blockers that decrease the SAN automaticity. Radiofrequency ablation of the SAN 
may be indicated in severe drug-refractory cases of inappropriate sinus tachycardia. 
2.4 Postural Orthostatic Tachycardia Syndrome (POTS) 
Refers to orthostatic decrease in blood pressure and sinus tachycardia in the absence of 
drugs or hypovolemia (1). 
3. Atrial Fibrillation 
Atrial fibrillation (AF) is a type of supraventricular arrhythmia characterized by presence of 
low amplitude fibrillatory waves on the ECG (Fig 3). The fibrillatory waves exhibit variable 
amplitude and shape and are placed irregularly. They are generated at a rate of 300-600 
beats/min. The resulting ventricular rhythm is irregularly irregular. However, the 
ventricular rhythm may be regular in AF in the patients with third degree atrioventricular 
block with an escape pacemaker or artificial pacemaker. 
 
Fig. 3. Atrial fibrillation 
3.1 Classification 
AF is considered to be paroxysmal if it terminates spontaneously within 7 days. If it continues 
for more than 7 days, it is considered to be persistent. Permanent AF persists for more than a 
year and is resistant to cardioversion. Lone AF is a term used to describe the occurrence of 
AF in patients younger than 60 years of age that do not have hypertension or evidence of 
any structural heart disease.  
3.2 Epidemiology 
AF is the most common cardiac arrhythmia encountered in clinical practice. It is also the 
most common cause of hospitalization among all the arrhythmias. Advanced age, obesity, 
hypertension, congestive heart failure, mitral and aortic valve disease are independent risk 
factors for development of AF.  
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3.3 Causes of AF 
Hypertension and hypertensive heart disease is by far the most common cause of AF. Other 
causes include ischemic heart disease, mitral valve disease, hypertrophic cardiomyopathy, 
dilated cardiomyopathy, pulmonary hypertension, and obesity with resultant obstructive 
sleep apnea. AF may be caused by reversible temporary causes such as excessive alcohol 
intake (holiday heart syndrome), myocardial infarction, pulmonary embolism, thoracic surgery, 
pericarditis and myocarditis. Hyperthyroidism is one of the correctable causes of AF.  
3.4 Clinical features 
AF may be symptomatic or asymptomatic. The most common symptoms of AF are 
palpitation, shortness of breath, tiredness and lightheadedness. It is often asymptomatic in 
elderly patients and those with persistent AF. Patients with AF may experience syncope at 
the conversion of AF to normal sinus rhythm from long sinus pause. Cerebrovascular 
accident (CVA) may be the initial manifestation of AF in patients with asymptomatic AF 
due to predisposition to thrombus formation in the atria, predominantly in the left atrial 
appendage due to chaotic and asynchronous atrial activity. It may also manifest as 
congestive heart failure due to tachycardia induced cardiomyopathy. 
3.5 Physical examination 
On physical examination, patients with AF often have irregularly irregular pulse. Patients 
often have pulse deficit, which is discordance between peripheral pulse and apical impulse. 
It results from short diastolic filling period for the ventricles during rapid AF resulting in 
low stroke volume and absence of peripheral pulse. There is variability in the intensity of 
the first heart sound on auscultation due to variable diastolic filling of the ventricles. 
3.6 Diagnostic evaluation 
History should be directed to assess the nature of AF (paroxysmal or persistent), nature of 
triggers, correctable causes such as excessive alcohol or caffeine intake, severity, frequency 
and duration of episodes of AF.  
Twenty-four hour Holter monitoring may be helpful in patients with frequent episodes of 
AF whereas an event monitor would be helpful in patients with sporadic symptoms for 
detection of the episodes of AF. 
Laboratory evaluation should include thyroid function tests to evaluate the thyroid function 
as a cause of AF. An echocardiogram is helpful to determine the left atrial size, left 
ventricular function and valvular heart disease. A stress test may be helpful for evaluation 
of ischemic heart disease as a cause of AF.  
3.7 Thromboembolic complications 
As described above, AF predisposes to thromboembolic complications such as CVA. 
However, the risk of these complications is not the same in all the individuals with AF. Thus 
it is imperative to stratify the risk of developing these complications. The risk for CVA is 
highest in patients with prior history of ischemic CVA and mitral stenosis whereas it is 
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lower in patients with lone AF. Gage et al developed a simple clinical scheme to stratify the 
patients on the basis of major risk factors. It is known by the acronym CHADS-2 that 
includes Congestive heart failure, Hypertension, Age  75 years , Diabetes mellitus and 
previous Stroke. Each of the first four risk factors is assigned 1 point and prior ischemic 
stroke or transient ischemic attack is assigned 2 points (2). There is a direct relationship 
between the annual risk of stroke and CHADS-2 score (Table 1). 
 
Score Annual risk (%) 
0 1.9 
1 2.8 
2 4.0 
3 5.9 
4 8.5 
5 12.5 
6 18.2 
CHADS-2 score is calculated by adding 1 point for each of recent congestive heart failure, hypertension, 
age 75 years and older, diabetes mellitus and 2 points for history of stroke or transient ischemic attack. 
Table 1. Annual stroke risk according to CHADS-2 score (2). 
The risk of thromboembolic complications is similar in patients with paroxysmal and 
persistent AF (3). 
3.8 Prevention of thromboembolic complications 
As discussed above, the risk of stroke increases with increase in the CHADS-2 score in 
patients with AF. The annual risk of stroke in patients with CHADS-2 score of 0 is 
approximately 1.9 %. In these patients, aspirin therapy alone is adequate due to the lower 
annual risk of stroke. Warfarin therapy is superior to aspirin in prevention of stroke (61 % 
vs. 18 %), however the risk of hemorrhagic complications is also higher and falls in the same 
range of 1-2 % annually (4, 5). Thus, considering the risk benefit ratio, aspirin therapy alone 
would be adequate in these patients. 
In patients with CHADS -2 score of 1, the annual risk of stroke is 2.8 %. The decision to use 
aspirin alone or warfarin therapy should be individualized and patient preference may be 
taken into consideration. The dose of aspirin used for prevention of stroke ranges from 81-
325 mg daily.  
In patients with CHADS-2 score >1, aspirin therapy alone is inadequate to decrease the risk 
of stroke. These patients should receive warfarin for prevention of stroke. The target 
international normalized ratio (INR) should be 2.0-3.0 during warfarin therapy. The risk of 
major bleeding with warfarin is between 1-2 % annually as described above and it increases 
with INR >3.0 (6). Advanced age should not be a deterrent to starting warfarin therapy (7).  
US-Federal Drug Administration (FDA) F recently approved direct thrombin inhibitors such 
as dabigatran for prevention of stroke in patients with non-valvular AF. It offers the 
advantage of fixed dosing and lack of the requirement for INR testing during therapy. 
Dabigatran given at a dose of 110 mg twice daily was associated with similar rates of stroke 
and systemic embolism as with warfarin and lower rates of major bleeding. When it was 
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administered at a dose of 150 mg twice daily, it was associated with lower rates of stroke 
and systemic embolism but similar rates of major hemorrhage (8). 
4. Acute management of AF 
In patients who present with an episode of AF and rapid ventricular response, control of 
ventricular rate should be the priority. It can be achieved with intravenous diltiazem or 
beta-blockers such as esmolol. However, if the patient is hemodynamically unstable, 
emergent transthoracic electric direct current (DC) cardioversion is appropriate.  
The decision to restore sinus rhythm after control of ventricular rate should be 
individualized based on nature of AF (paroxysmal or persistent), duration of AF, presence 
of symptoms, age, prior episodes and antiarrhythmic and anticoagulation therapy.  
The decision making for restoration of sinus rhythm in patients with AF has two 
components: one is early vs. late cardioversion and second is electrical cardioversion vs. 
pharmacologic cardioversion.  
Early cardioversion is attempted in patients with AF lasting less than 48 hours and those 
who have been on therapeutic anticoagulation of 3-4 weeks prior to cardioversion. Late 
cardioversion is attempted in patients with left atrial appendage thrombus on 
transesophageal echocardiography (TEE), if the duration of AF is > 48 hours or if the 
duration is unclear and those with suspected correctable cause of AF. When the duration of 
AF is > 48 hours or unclear, the other option to avoid delayed cardioversion is TEE for 
surveillance of left atrial thrombus followed by cardioversion if there is no evidence of 
thrombus. 
Cardioversion can be done using either electrical or pharmacologic means. Pharmacologic 
cardioversion can be performed by intravenous administration of ibutilide (success rate 60-
70 %), amiodarone (success rate 40-50%) or procainamide (success rate 30 %). After infusion 
of ibutilide, patients should be monitored for polymorphic ventricular tachycardia that can 
occur as an adverse effect. In patients without structural heart disease, oral agents such as 
propafenone (300-600mg) or flecainide (100-200mg) can be administered for cardioversion. 
The success rate of transthoracic electrical cardioversion is very high (95 %). In some cases, 
electrical cardioversion may be required after administration of antiarrhythmics for 
maintenance of sinus rhythm. 
4.1 Long-term management of AF 
As far as long-term management of AF is considered, several studies have compared rate 
control (controlling ventricular rate) strategy vs. rhythm control (restoration of sinus 
rhythm) strategy. The largest of these trials (AFFIRM) failed to show any benefit of rhythm 
control strategy over rate control strategy. Rhythm control strategy in this study was 
associated with higher rates of hospitalization and adverse drug effects of antiarrhythmic 
therapy that were used for restoration of sinus rhythm (9). However, the decision to pursue 
rate control or rhythm control strategy is a complex one and should be individualized after 
taking several factors into account including, age, comorbidities, duration of AF, left atrial 
dimensions, presence of symptoms, response to prior cardioversions. In patients > 65 years 
of age with asymptomatic or minimally symptomatic AF, it would be reasonable to pursue 
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rate control strategy whereas symptomatic AF in younger and older age patients should be 
offered the option of rhythm control.  
As far as antithrombotic therapy is considered, all patients with either paroxysmal or 
persistent AF should receive antithrombotic therapy with either aspirin or warfarin based 
on their risk stratification irrespective of their symptom status as described above. 
4.2 Pharmacologic rate control 
The goal for heart rate control in AF is to maintain heart rate less than 80 beats/min at rest 
and less than 110 beats /min during activity. Oral agents available for heart rate control in 
AF include digitalis, beta-blockers, calcium channel blockers and amiodarone. The first line 
agents for rate control are beta-blockers such as metoprolol and calcium channel blockers 
such as diltiazem and verapamil. Digitalis is useful to control heart rates due to its vagotonic 
effects but may not be adequate as a single agent for rate control during exertion. It is useful 
in patients with systolic heart failure due to its effects on prevention of heart failure 
hospitalization. Although amiodarone is not routinely used for rate control, it is useful in 
patients with contraindications for calcium channel blockers (such as systolic heart failure) 
and beta-blockers (such as reactive airway disease).  
4.3 Pharmacologic rhythm control 
A pharmacologic rhythm control strategy consists of either chronic prophylactic therapy 
with antiarrhythmic drugs or single pill in the pocket approach at each symptomatic 
recurrence of AF by typically using class IC (flecainide, propafenone) drugs depending on 
the frequency and severity of symptoms. Amiodarone is by far the most effective agent for 
rhythm control (maintenance of sinus rhythm) among all the antiarrhythmic agents. Its 
adverse effects including pulmonary and liver toxicity and effects on thyroids limit its use.  
Ventricular arrhythmias are common from all the antiarrhythmic agents and they are poorly 
tolerated due to their adverse effects. Use of antiarrhythmic therapy for rhythm control 
should be individualized based on comorbidities such as hypertension, left ventricular 
hypertrophy, congestive heart failure and ischemic heart disease.  
4.4 Catheter ablation of AF 
Catheter ablation of AF should be offered to patients but requires appropriate selection of 
patients. Patients with lone paroxysmal AF and minimal structural heart disease are the 
ideal candidates for this procedure. It may be appropriate to consider this approach as first 
line therapy in patients younger than 35 years of age with symptomatic AF and SAN 
dysfunction that complicates antiarrhythmic drug therapy. Patients with persistent and 
symptomatic AF and minimal structural heart disease who have failed at least one 
antiarrhythmic drug therapy may be offered catheter ablation.  
Isolation of pulmonary veins alone is often sufficient in patients with paroxysmal AF. 
However, in patients with persistent AF, a variety of ablation strategies have been used. The 
success rate for AF ablation is higher for paroxysmal AF (70-80%) than persistent AF (50 %). 
The risk of major complication after AF ablation is approximately 5-6 % and most common 
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complications include cardiac tamponade, pulmonary vein stenosis and stroke. 
Atrioesophageal fistula is a rare but lethal complication of this procedure. 
4.5 Other nonpharmacologic approaches to AF management 
AV nodal ablation and insertion of pacemaker may be considered in patients with persistent 
AF and inadequate ventricular rate control with medications or intolerance to medications, 
and those with failed attempt at catheter ablation of AF. 
Maze procedure is a surgical procedure developed by Cox that involves multiple incisions 
involving the right and left atria but requires open thoracotomy and cardiopulmonary 
bypass (10). It may be considered concomitantly in patients who are undergoing coronary 
bypass graft surgery or valvular repair or replacement.  
5. Atrial tachycardia 
Atrial tachycardias are broadly classified into focal and macroreentrant types based on 
management. Focal atrial tachycardias originate from activation of one particular focus in 
the atria where as macroreentrant tachycardias use a relatively large reentrant circuit using 
conduction barriers for creation of the circuit. 
5.1 Atrial flutter 
Atrial flutter is the most common type of macroreentrant atrial tachycardia. The reentrant 
circuit of atrial flutter is constrained anteriorly by the tricuspid annulus and posteriorly by 
the crista terminalis and eustachian ridge. A typical atrial flutter circulates in a 
counterclockwise fashion around the tricuspid annulus and atypical flutter circulates in a 
clockwise fashion 
Atrial rate during atrial flutter varies between 200-300 beats/min. Ventricular response to 
atrial flutter is determined by factors such as conduction through the AVN and concomitant 
antiarrhythmic drug therapy. On ECG, atrial flutter manifests as recurring, regular, saw 
tooth flutter waves (Fig 4). 
 
Fig. 4. Typical atrial flutter 
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5.2 Clinical features 
Atrial flutter occurs as a result of valvular heart disease such as mitral and tricuspid 
stenosis, pulmonary embolism, prior AF ablations, atrial septal defects that result in atrial 
dilation, thyrotoxicosis, alcoholism and following surgeries for congenital heart disease. 
Patients in atrial flutter often describe symptoms such as palpitations, diaphoresis, 
lightheadedness and dizziness. 
On physical examination, patients have constant intensity of the first heart sound if the 
ventricular response is constant and rapid jugular venous pulsations. Carotid sinus massage 
often slows down the ventricular response but does not terminate it. 
5.3 Management 
Atrial flutter is much more difficult to rate control than AF. Thus, transthoracic synchronous 
DC cardioversion may be offered as an initial treatment to patients with atrial flutter. 
Pharmacologic agents such as procainamide and ibutilide are often successful in conversion 
of atrial flutter to sinus rhythm, however ibutilide is associated with Torsades de pointes (Tdp) 
arrhythmia. If atrial flutter persists despite cardioversion, class IA and IC agents or low dose 
amiodarone may be helpful for prevention of recurrences. However, patients should be on 
AV nodal blocking agent during this therapy to prevent faster ventricular response after 
slowing of atrial flutter rate that may allow more frequent AV nodal conduction.  
The success rate for ablation of cavo-tricuspid isthmus dependent atrial flutter is 90-100%, 
thus it may be offered as an alternative to drug therapy as an initial therapy in patients with 
these types of atrial flutter.  
As far as acute management of atrial flutter is considered, ventricular rate control can be 
attempted with intravenous diltiazem and verapamil or beta-blockers such as esmolol and 
metoprolol. Digoxin may be added if the combination of beta-blockers and calcium channel 
blockers is inadequate for ventricular rate control. Intravenous amiodarone has been found 
to be successful in rate control of atrial flutter.  
The recommendations for antithrombotic therapy in patients with atrial flutter are the same 
as AF. 
6. Focal atrial tachycardia 
Focal atrial tachycardias originate from a single atrial focus and generally exhibit atrial rates 
between 150-200 beats/min. They typically occur in short bursts, however, may be 
incessant. On ECG, focal atrial tachycardia is differentiated from sinus tachycardia by P 
wave morphologies that are characteristically different in contour compared to sinus P wave 
morphology and from atrial flutter by presence of isoelectric interval in all the ECG leads. 
Right atrial tachycardias produce positive or biphasic P waves in lead V1 where as left atrial 
tachycardias produce negative P waves.  
Focal atrial tachycardia occurs commonly in patients with structural heart disease, cor 
pulmonale, digitalis toxicity and electrolyte abnormalities. Stimulants such as caffeine can 
precipitate focal atrial tachycardia.  
www.intechopen.com
 
Definition, Diagnosis and Treatment of Tachycardia 
 
51 
On examination, patients have variable intensity of the first heart sound due to variable 
conduction through the AVN with resultant variable R-R interval, and increased number of a 
waves on the jugular venous pulse. Carotid sinus massage or intravenous adenosine results in 
increased vagal activity and decrease in ventricular response but rarely terminates it.  
Focal atrial tachycardia in patients on digitalis can be due to toxicity. Digitalis should be 
discontinued in these patients and electrolyte abnormalities such as hypokalemia should be 
corrected. Administration of digitalis antibodies should be considered in patients with rapid 
ventricular response after correction of electrolyte abnormalities. In patients who are not 
taking digitalis, beta-blockers, calcium channel blockers or digitalis may be considered for 
control of ventricular response. Persistent atrial tachycardia may require administration of 
class IA, IC or III agents. Patients intolerant of antiarrhythmic therapy or non compliant 
with antiarrhythmic therapy can be offered catheter ablation for elimination of the 
tachycardia based on the location of the focus and local expertise in ablation.  
7. Multifocal (chaotic) atrial tachycardia 
Multifocal atrial tachycardia is characterized by presence of variable P wave morphologies 
and PR intervals due to origin of this tachycardia from multiple foci (Fig 5). At least 3 
different types of P wave contours are necessary for the diagnosis. 
 
Fig. 5. Multifocal atrial tachycardia 
It occurs in elderly patients with chronic obstructive pulmonary disease and congestive 
heart failure. It may be rarely caused by digitalis or theophylline administration.  
Management of this tachycardia should be directed at treatment of underlying disease. 
Calcium channel blockers such as verapamil and diltiazem or amiodarone are helpful in 
management. Potassium and magnesium should be replaced. Beta-blockers are avoided in 
patients with reactive airway disease.  
8. AV nodal reentrant tachycardia 
AV nodal reentrant tachycardia (AVNRT) is a reentrant form of SVT involving AV junction. 
On surface ECG, it is characterized by presence of regular R-R intervals, narrow QRS 
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complexes (in absence of previous conduction defects), sudden onset and termination and 
ventricular rates between 150-250 beats/min (Fig 6).  
 
Fig. 6. AV nodal reentrant tachycardia 
Conduction of the electrical impulses from the atria to the AVN occurs over slow and fast 
pathways. A premature atrial complex (PAC) or rarely a premature ventricular complex 
(PVC) often initiates this tachycardia. PAC conducts to the ventricle over the slow pathway 
during the refractory period of the fast pathway resulting in prolonged PR interval before 
the initiation of the tachycardia. After conduction over the slow pathway it returns and 
conducts over the fast pathway, which is no longer refractory and thus initiating the circus 
movement. This is the mechanism of a typical AVNRT. Atypical form of AVNRT is 
characterized by anterograde conduction to the ventricles over the fast pathway and 
retrograde conduction to the atrial over the slow pathway. Thus atrial activation is slightly 
before, during or slightly after the activation of QRS complex. If atrial activation occurs after 
the QRS complex, it manifests on the surface ECG as pseudo-r’ in lead V1 and pseudo-S 
waves in leads II, III and aVF.  
Typical form of AVNRT is characterized by short ventriculoatrial conduction (VA) interval 
due to near simultaneous activation of atria and ventricles where as atypical form of 
AVNRT is characterized by longer VA interval due to activation of ventricles over the fast 
pathway and retrograde activation of atria over the slow pathway. Typical AVNRT is a 
short R-P type of SVT due to faster retrograde conduction to the atria over the fast pathway 
whereas atypical AVNRT is a long R-P type SVT due to longer retrograde conduction to the 
atria over the slow pathway. 
8.1 Clinical features 
AVNRT usually occurs in patients with no structural heart disease. It manifests with 
symptoms such as palpitations, lightheadedness, anxiety, syncope, diaphoresis, angina and 
worsening of presence of new heart failure symptoms. It occurs in third or fourth decade of 
life. It is more prevalent in women than in men. 
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8.2 Management of acute attack 
Patients with infrequent episodes of AVNRT that are well tolerated can be simply reassured. 
Vagal maneuvers such as carotid sinus massage, gagging, and Valsalva maneuver may 
sometimes be helpful in termination of the episode. Adenosine administered in doses of 6-12 
mg is the initial drug of choice in patients with suspected AVNRT. However, it should be 
kept in mind that adenosine is contraindicated in patients with asthma. Calcium channel 
blockers such as diltiazem or verapamil administered intravenously may also be helpful in 
termination of the acute attack. Digitalis is rarely used in acute attack due to its slower onset 
of action. However, it may increase the success rate of vagal maneuvers. Beta-blockers are 
rarely used due to their inferior efficacy as compared to calcium channel blockers in 
termination of acute episode. DC synchronized cardioversion may be required in patients 
with hemodynamic instability due to AVNRT.  
8.3 Prevention of recurrences 
Long term medical therapy or radiofrequency ablation for prevention of recurrences is 
recommended in patients with frequent and severe episodes of AVNRT. Long acting 
calcium channel blockers, long acting beta-blockers or digitalis may be helpful in prevention 
of recurrence.  
Radiofrequency ablation can be offered as an initial therapy in patients who are 
symptomatic from frequent and severe episodes. It should also be offered in patients who 
are intolerant or reluctant to pharmacologic therapy for prevention of recurrences. It has a 
very high success rate (95 %) and very low complication rate.  
9. AV reciprocating (reentrant) tachycardia 
AV reciprocating tachycardia (AVRT) occurs due to reentry over accessory pathways that 
connect the atrium or AVN to the ventricle outside the normal AVN and His- Purkinje 
system. These pathways can conduct impulses either anterogradely from the atria to the 
ventricles or retrogradely from the ventricles to the atria. When the conduction occurs 
anterogradely over the accessory pathway (manifest conduction), it results in pre-excited 
QRS complex where as if the accessory pathway conducts only retrogradely (concealed 
conduction), it does not produce ventricular preexcitation. Preexcited QRS complex with 
tachycardia is referred to as Wolf Parkinson White (WPW) syndrome. 
9.1 Reentry over a concealed pathway (Orthodromic AVRT) 
Orthodromic AVRT results from anterograde conduction from the atria to the ventricles 
over the normal AV nodal conduction system and retrograde conduction from the ventricles 
to the atria over the accessory pathway. Thus there is no ventricular preexcitation during the 
tachycardia and the accessory pathway is considered to be concealed.  
On ECG, this results in retrograde P waves that occur in the ST segment or T wave portion 
of the ECG. The contour of P waves is different from sinus P waves due to eccentric 
activation of the atria in most cases.  
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Diagnosis is usually done during an electrophysiology study (EPS), where a PVC activates 
the atria prior to activation of the His bundle. Also if the PVC activates the atria when His 
bundle is supposed to be refractory, presence of accessory pathway is almost certain. The 
VA interval remains constant over a wide range of coupling intervals of the PVC as most of 
the accessory pathways exhibit all or none conduction unlike conduction over the AVN 
which shows decremental property at higher rates. The VA interval is < 50% of R-R interval.  
9.2 Clinical features 
Tachycardia rates in these patients tend to be faster than AVNRT and are around 200 
beats/min. Patients can present with palpitations, anxiety, presyncope or syncope. On 
physical examination, they have regular pulse and constant intensity first heart sound due 
to constant R-R interval.  
9.3 Management 
As the tachycardia circuit involves the AVN and the fact that conduction over the accessory 
pathway occurs only retrogradely, the acute management of orthodromic AVRT is similar to 
AVNRT. Vagal maneuvers, adenosine, calcium channel blockers or digitalis that produce 
transient AV block may result in termination of this tachycardia. Chronic prophylactic 
therapy involves administration of antiarrhythmic drugs that prolong the conduction over 
the accessory pathway such as class I and class III drugs or radiofrequency ablation. 
Radiofrequency ablation of the accessory pathway has high success rates, low complication 
rate and should be considered for symptomatic patients early in their management or those 
with intolerance to antiarrhythmic therapy. 
10. Preexcitation syndrome 
Preexcitation syndrome results from activation of the ventricle in part or entirely from atrial 
impulses that are conducted over the accessory pathway that conducts anterogradely. Three 
features of WPW syndrome are – 
1. PR interval less than 120 ms 
2. Presence of slow up or down sloping QRS complex in some leads, often called as delta 
waves 
3. Secondary ST-T wave changes that are generally directed in direction opposite to the 
major delta or QRS vector. 
Accessory pathways can be atriohisian that connect the atria to the His bundle, atriofascicular 
that connect atria to one of the fascicles, nodofascicular that connect the AVN to the fascicles, 
or fasciculoventricular that connect the fascicles to the ventricle. Mahaim fibers are 
atriofascicular or nodofascicular fibers that exhibit progressive increase in the AV interval in 
response to atrial overdrive pacing unlike the usual atrioventricular accessory pathway. 
Location of the accessory pathways can be predicted by careful analysis of the ECG. 
Accessory pathways that conduct to the right ventricle produce negative delta waves and QRS 
in lead V1 whereas those conducting to the left ventricle produce positive delta wave and QRS 
in lead V1. Posteroseptal pathways produce negative delta waves or QRS complex in leads II, 
III and aVF. Left free wall pathways produce negative or isoelectric delta wave in lateral leads. 
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Right free wall pathways produce left axis deviation where as if the accessory pathway is 
located in the right ventricle, presence of inferior axis indicates anteroseptal pathway. 
Accessory pathways have a longer refractory period during long cycle lengths. Thus a PAC 
can result in conduction over the normal AVN and His bundle complex as the accessory 
pathway is refractory but when the impulse arrives to the ventricles, it has recovered 
excitability and can conduct retrogradely resulting in reciprocating orthodromic AVRT. If 
the conduction occurs anterogradely over the accessory pathways and retrogradely over the 
AVN-His bundle, it is referred to as antidromic AVRT.  
10.1 Permanent form of AV junctional reciprocating tachycardia (PJRT) 
Rfrom very slowly conducting posteroseptal accessory pathway. It is maintained by 
anterograde conduction over the AVN and retrograde conduction over the accessory pathway. 
10.2 Clinical features 
Incidence of preexcitation syndrome is approximately 1.5/1000 among healthy adults. Left 
free wall accessory pathway is the most common type of accessory pathway. Patients with 
Ebstein anomaly often have right-sided accessory pathways. The prevalence is higher in men 
and decreases with age. The frequency of tachycardia however increases with age with 
reciprocating tachycardia being the most common (80 %) of patients followed by AF (15-30 %). 
The incidence of sudden death is very rare (<0.1 %). Patients who have ventricular fibrillation 
(VF) have ventricular cycle lengths in the range of 240 ms or less. Presence of only intermittent 
preexcitation during sinus rhythm, abrupt loss of conduction during administration of 
procainamide are suggestive of longer refractory period of accessory pathway. 
10.3 Management of preexcitation syndrome and tachycardia 
Patients who have preexcitation on ECG with no history of palpitations or tachycardia may 
be managed conservatively without any further electrophysiologic evaluation. However, 
patients with preexcitation on the ECG and history of palpitations or documented 
tachycardia need further treatment. Therapeutic options include pharmacologic 
management and radiofrequency ablation.  
While considering pharmacologic management of preexcited tachycardia and patients with 
accessory pathway (concealed or manifest), it is important to understand the effects of 
various drugs on these pathways. Class IA drugs increase the refractoriness of accessory 
pathways. Calcium channel blockers, adenosine, and digitalis act on AVN where as class IC 
agents (flecainide, propafenone) and class III agents such as amiodarone and sotalol increase 
the refractoriness of both AVN and accessory pathway. 
10.4 Management of acute episode 
Management of orthodromic AVRT (using the concealed accessory pathway) has been 
discussed above.  
Patients with preexcited tachycardias suspected by presence of anomalous QRS complexes, 
or know prior history of preexcitation from previous ECGs, require drugs that prolong the 
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refractoriness of the accessory pathway (such as procainamide) often coupled with drugs 
that prolong the refractoriness of AVN to break the reentry circuit. However, patients that 
are hemodynamically unstable require electrical DC cardioversion. 
10.5 Prevention of recurrence 
Radiofrequency ablation of the accessory pathway has become the treatment of choice in 
patients with accessory pathway for prevention of recurrence due to its high success rate 
and low complication rate. However, if transvenous catheter ablation is unsuccessful 
epicardial ablation or surgical interruption of the accessory pathway may be necessary. 
Drug therapy is an alternative approach to ablation however the effect of drugs on accessory 
pathways is unpredictable. Class IC agents, amiodarone and sotalol or combination of class 
IC agent and beta blocker may be effective as they prolong refractoriness in the accessory 
pathway as well as AVN. Further testing (such as exercise, isoproterenol infusion) is 
essential to be certain that ventricular response is controlled in patients with AF that are 
started on these agents.  
11. Ventricular tachycardia 
Ventricular tachycardia (VT) is defined as 3 or more consecutive premature ventricular 
complexes. It is considered to be nonsustained if it lasts less than 30 seconds and sustained if 
it last more than 30 seconds or requires termination due to hemodynamic collapse.  
VT originates distal to His bundle in the ventricular muscle, specialized conduction system 
or combination of both tissues. It can occur in patients with no structural heart disease, as a 
part of inherited syndromes or in patients with structural heart disease.  
On ECG, it is characterized by wide QRS complexes that are mostly regular, with rates varying 
between 70-250 beats/min and ST-T vector directed opposite to the QRS vector (Fig 7). 
 
Fig. 7. Ventricular tachycardia 
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11.1 Wide QRS complex tachycardia and differentiation of VT from SVT with aberrant 
conduction 
Differential diagnosis of wide QRS complex tachycardia includes VT, SVT with aberrant 
conduction due to rate dependent bundle branch block, SVT with preexisting bundle branch 
block, SVT /AF with anterograde conduction over the accessory pathway, or antidromic 
AVRT. VT is however the most common cause of tachycardia with wide QRS complex.  
The features that favor the diagnosis of VT include – 
1. Presence of underlying structural heart disease, or myocardial infarction 
2. Duration of QRS complex greater than 140 ms 
3. Presence of fusion beats (QRS complexes originating from co-activation of ventricles by 
ventricular and supraventricular rhythm on ECG) 
4. Presence of capture beats (ventricular activation from supraventricular beats with 
contour different from rest of the complexes) 
5. Presence of conduction disturbances on the baseline ECG and QRS complexes different 
in configuration compared to baseline ECG 
6. AV dissociation i.e. no relation between ventricular and supraventricular rhythm; it is 
highly specific but not very sensitive 
7. Positive or negative concordance in precordial leads (all QRS complexes in precordial 
leads are either negative or positive) 
8. In the presence of right bundle branch block pattern, the initial pattern of activation is 
different from activation by sinus initiated QRS complexes, larger amplitude of R wave 
compared to R’ and rS or QS pattern in lead V6 
9. In the presence of left bundle branch block, R wave in V1 is longer than 30 ms and 
duration of start of R wave to nadir of S wave in V1 is longer than 60 ms and qR or qS 
pattern in lead V6 
10. Extreme left axis deviation (“northwest axis”) on the ECG 
Electrophysiologic characteristics of VT include negative HV interval and dissociated His 
bundle deflections from ventricular activation. 
11.2 Clinical features 
VT can occur as nonsustained or sustained episode. Nonsustained VT is usually well 
tolerated, however patients may complain of palpitations and presyncopal symptoms. 
Sustained VT can be hemodynamically stable or it may present has unstable runs finally 
degenerating into ventricular fibrillation. 
Ischemic heart disease is by far the most common cause of VT followed by cardiomyopathy. 
Patients with sustained monomorphic VT have myocardial substrate different from patients 
with ventricular fibrillation and often have reduced left ventricular ejection fraction, slowed 
intraventricular conduction and previous myocardial infarction.  
Reduced left ventricular function, inducibility of sustained VT during electrophysiologic 
study, T wave alternans are some of the strong predictors of poor outcome in patients with 
VT (11).  
Prognosis of patients with idiopathic VT, in absence of structural heart disease is good.  
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11.3 Acute management of sustained ventricular tachycardia 
Sustained VT in hemodynamically stable patients can be terminated pharmacologically with 
administration of one of the antiarrhythmics such as amiodarone, lidocaine, procainamide 
or sotalol. Amiodarone administered by intravenous infusion is often effective. If the 
arrhythmia is non responsive to medical therapy or if patient is hemodynamically unstable, 
electrical DC cardioversion can be used. Ventricular pacing using transvenous catheter 
inserted into the right ventricle at rates faster than VT can terminate VT however runs the 
risks of degenerating VT into ventricular flutter or fibrillation. 
After stabilization of the patient, one should look for reversible conditions such as ischemia, 
electrolyte abnormalities, and drugs as a cause of VT. 
11.4 Therapy for prevention of recurrences 
Symptomatic nonsustained VT in patients with normal left ventricular function can be 
treated with beta-blockers. Patients refractory to beta-blockers can be treated with class IC 
agents, sotalol or amiodarone. 
Asymptomatic nonsustained VT in a patient with no evidence of structural heart disease 
does not require treatment. 
11.5 Primary prevention 
Patients with nonsustained VT and structural heart disease with a left ventricular ejection 
fraction of <0.35 to 0.40 should undergo EPS and implantable cardioverter defibrillator 
(ICD) implantation if they have inducible VT (12,13). 
Patients with nonsustained VT, prior myocardial infarction and left ventricular ejection 
fraction of <0.30 do not require EPS and can directly undergo ICD placement (14) 
Patients with ischemic and non-ischemic cardiomyopathy, left ventricular ejection fraction of 
<0.35 and NYHA class II or III heart failure should undergo ICD implantation due to 7 % 
absolute decrease in mortality (15). Amiodarone is the next best therapy in patients with heart 
failure, non-ischemic cardiomyopathy ejection fraction of <0.40, and frequent PVCs (16). 
11.6 Secondary prevention 
Survivors of sudden cardiac arrest or patients with sustained VT resulting in hemodynamic 
compromise and poor left ventricular function should be offered ICD implantation (17, 18). 
Patients who refuse ICD implantation, treatment with amiodarone is the next best therapy 
(19). 
Optimal therapy for patients with sustained VT and normal left ventricular function is 
unknown however empiric amiodarone appears to be safe.  
Radiofrequency ablation is effective in patients with idiopathic VT; however it is less 
effective in patients with structural heart disease and depressed LV function. It may be 
effective as an adjunctive therapy in patients with recurrent ICD shocks due to VT that is not 
responsive to combination of antiarrhythmic therapy. 
www.intechopen.com
 
Definition, Diagnosis and Treatment of Tachycardia 
 
59 
12. Ventricular arrhythmia in arrhythmogenic right ventricular 
cardiomyopathy 
Arrhythmogentic right ventricular cardiomyopathy (ARVC) is familial and progressive 
cardiomyopathy of the right ventricle. VT in ARVC is caused by reentry. It has left bundle 
branch contour due and often resembles right ventricular outflow tract tachycardia. Patients 
may be asymptomatic or may manifest signs and symptoms of right heart failure. ECG 
during sinus rhythm shows right bundle branch block pattern and T wave inversions in 
leads V1 through V3. Epsilon wave (which is a terminal notch in the QRS) can be present in 
these leads. ICDs are preferable for the treatment of this condition due to progressive nature 
of the disease.  
13. Inherited arrhythmia syndromes 
13.1 Catecholaminergic polymorphic ventricular tachycardia 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited VT that 
occurs in children and adolescents without any structural heart disease or surface 
electrocardiographic abnormalities. It is stress induced and patients present with syncope or 
aborted sudden death. VT is bidirectional in nature and may eventually degenerate into 
polymorphic VT with exercise. The treatment of choice is beta-blockers and ICD. Patients 
should be instructed to avoid vigorous exercise.  
13.2 Brugada syndrome 
It is an inherited form of idiopathic ventricular fibrillation that occurs commonly in young 
healthy Southeast Asians. These patients have no structural heart disease. On ECG, they 
have ST segment elevation in the precordial leads at rest. Mutations in the sodium channel 
genes (SCN5A) and calcium channel have been identified in several families. Phase 2 reentry 
due to heterogenous loss of action potential dome is thought to be responsible for 
ventricular arrhythmias. There is no pharmacologic treatment available and ICD 
implantation is the only treatment that is effective for prevention of sudden death. 
13.3 Torsades de pointes 
Tdp refers to a VT characterized by presence of QRS complexes with varying amplitude that 
twist around the isoelectric baseline (Fig 8). The rate usually varies from 200-250 beats/min. 
It occurs in patients with prolonged ventricular repolarization manifesting as prolonged QT 
interval.  
VT that is similar to Tdp but occurs in patients without QT prolongation is called 
polymorphic ventricular tachycardia.  
Tdp can occur in two settings. Late PVCs may discharge during termination of long T wave 
that precipitates the episode of VT or short coupled variant occurring due to close-coupled 
PVC. Tdp is thought to occur from early afterdepolarizations.  
The common predisposing factors for Tdp include severe bradycardia, hypokalemia, use of 
class IA or III antiarrhythmic drugs, QT interval prolonging drugs or congenital long QT 
syndrome.  
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Fig. 8. Torsades de pointes 
In patients with Tdp, the reversible cause should be corrected such as discontinuing Class IA 
or III antiarrhythmic, or QT prolonging drug. In patients with acquired long QT syndrome, 
intravenous magnesium should be given. This is followed by temporary atrial or ventricular 
pacing. Isoproterenol infusion can be tried prior to starting pacing.  
Polymorphic VT however can be treated with standard antiarrhythmic drugs.  
13.4 Long Q-T syndrome 
Corrected long QT interval (QTc) is less than 460 ms for men and 470 ms for women. 
Patients with long QT syndrome have prolonged QT interval and the risk for life 
threatening arrhythmias increases with length of QTc.  
Long QT syndrome can be congenital or acquired. Congenital long QT syndrome is usually 
due to inherited channelopathies. Acquired form of long QT syndrome as described above is 
caused by electrolyte abnormalities such as hypokalemia, drugs such as class IA and III 
antiarrhythmics, tricyclic antidepressants, phenothiazines, central nervous system lesions, 
and severe bradyarrhythmias.  
Patients with long QT syndrome may present with syncope, however sudden death may the 
initial manifestation in pediatric patients. High risk factors for sudden death in patients with 
long QT syndrome include family history of sudden death and prior history of syncopal 
episodes.  
In patients with idiopathic long QT syndrome, stress testing, electrocardiographic 
monitoring during various stimuli such as auditory stimuli, psychological stress, sudden 
exposure to cold valsalva maneuver can all be helpful to determine the risk of life 
threatening arrhythmias. ECG should be obtained for all family members in the presence of 
symptoms in the proband.  
www.intechopen.com
 
Definition, Diagnosis and Treatment of Tachycardia 
 
61 
Tdp often develops during bradycardia in patients with acquired forms of long QT syndrome.  
Idiopathic long QT syndrome patients, who are asymptomatic, have no family history of 
sudden cardiac death, and QTc shorter than 500ms need no therapy, however beta-blockers 
are generally recommended. 
Patients with above risk factors but no syncopal episodes or aborted sudden death should 
be treated with beta-blockers. 
Patients with syncope and aborted sudden death require ICD implantation. These patients 
should also be treated with beta-blockers.  
Patients who continue to have symptoms despite maximal therapy can be treated with left 
sided cervicothoracic sympathetic ganglionectomy. 
For treatment of Tdp from acquired long QT syndrome, refer to the discussion above.  
13.5 Short QT syndrome 
QT interval less than 350 ms at heart rates less then 100 beats/min is generally accepted as 
short QT interval. Short QT interval syndrome is an inherited disorder due to gain of function 
mutations in the genes that are responsible for long QT syndrome. It is associated with 
increased risk of ventricular fibrillation and sudden death. Patients are also predisposed to 
development of AF. In patients with short QT interval, high-risk features include history of 
syncope, family history of sudden death, palpitations, or AF. Reversible causes of short QT 
interval such as hyeprcalcemia, hyperthermia, and digitalis need to be excluded before making 
the diagnosis. ICDs are the treatment of choice in symptomatic patients with short QT 
syndrome. Antiarrhythmic agents such as quinidine have been found to be effective (20). 
14. Idiopathic ventricular tachycardia and ventricular fibrillation 
Idiopathic VT is a monomorphic VT occurring in patients with no structural heart disease. 
There are three distinct forms – outflow tract VT, annular VT, and fascicular VT. Prognosis 
for these patients is good and they are often amenable to ablation. 
Idiopathic ventricular fibrillation occurs in less than 10 % cases of out of hospital cardiac 
arrest. Association with early repolarization has been suggested in some studies (21). 
Recurrences can occur and ICD implantation is the treatment of choice. It can occur due to 
short-coupled PVCs in which case ablation of PVC might be helpful to prevent recurrences. 
14.1 Bidirectional ventricular tachycardia 
It is characterized by QRS complexes with right bundle branch block pattern with 
alternating polarity and regular rhythm. It occurs in patients with digitalis toxicity and 
CPVT. In patients with digitalis excess, digoxin-binding antibodies should be given in 
addition to antiarrhythmic therapy such as lidocaine or phenytoin.  
15. Bundle branch reentrant ventricular tachycardia 
It is reentrant tachycardia due to a circuit established over the bundle branches or fascicles. 
It results in monomorphic sustained VT and is usually seen in patients with structural heart 
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disease. Therapy is similar to other types of VT. Pace termination is effective in acute setting 
and radiofrequency ablation is effective in elimination of VT. 
15.1 Ventricular flutter and ventricular fibrillation 
Ventricular flutter is characterized by regular large oscillations occurring at a rate of 150 -300 
beats/min where as ventricular fibrillation is characterized by irregular undulations of 
varying amplitude and contour (Fig 9). 
 
Fig. 9. Ventricular fibrillation 
15.2 Clinical features 
VT often precedes ventricular fibrillation; however it is not a rule. It is most commonly 
caused by coronary artery disease. Other causes include hypoxia, and antiarrhythmic drug 
therapy. It may occur during pace termination of VT that may degenerate into ventricular 
fibrillation. 
Patients with ventricular fibrillation present with fainting episode, syncope, loss of 
consciousness, apnea and if the corrective measures are not taken, the event is fatal within 3-
5 minutes. 
15.3 Prognosis 
Poor prognostic factors in resuscitated patients from ventricular fibrillation include 
decreased left ventricular ejection fraction, regional wall motion abnormalities, congestive 
heart failure, presence myocardial infarction in absence of an acute event and patients with 
anterior myocardial infarction complicated by ventricular fibrillation. Overall, prognosis of 
resuscitated patients from ventricular fibrillation patients is better than those presenting 
with asystole.  
15.4 Management 
There are three components to management of patients with sudden cardiac arrest from 
ventricular fibrillation – immediate resuscitation, search for etiology of the event and 
prevention of recurrence. 
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First of all, immediate resuscitative measures should be undertaken in patients with sudden 
cardiac arrest as per the advanced life support guidelines. The key to better outcome and 
survival in patients with ventricular fibrillation is early defibrillation. Nonsynchronized 
direct current shock (defibrillation) using 200 to 400 Joules is usually adequate. The shock 
energy required is low if defibrillation is done early. 
After patients are stabilized, further evaluation should be directed towards the etiology of 
the event and correcting it if possible (such as correction of ischemia, or electrolyte 
abnormalities).  
Pharmacologic approaches to prevent recurrences include intravenous administration of 
antiarrhythmic agents such as amiodarone, lidocaine or procainamide. Amiodarone tends to 
be the most effective of all. Pharmacologic approaches for prevention of recurrences should 
be used until the etiology of the event is identified. Patients with continued risk of VT or VF 
should be offered ICD placement if the etiology of the event is irreversible.  
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